Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) are treated with vasodilators, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylyl cyclase activators, and prostacyclin. Despite recent advances in pharmacotherapy for individuals w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavasin, Maria A, Demos-Davies, Kimberly M, Schuetze, Katherine B, Blakeslee, Weston W, Stratton, Matthew S, Tuder, Rubin M, McKinsey, Timothy A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255666/
https://www.ncbi.nlm.nih.gov/pubmed/25425003
http://dx.doi.org/10.1186/s12967-014-0314-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255666/
https://www.ncbi.nlm.nih.gov/pubmed/25425003
http://dx.doi.org/10.1186/s12967-014-0314-y

Ejemplares similares